DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 28 Sept, 23:12 UTC

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections. The post DreaMed Wins FDA Clearance for…

science

Sources

• T2DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection RegimensFierce Biotech / Fierce Healthcare / MedCity / GEN28 Sept, 23:12